Top

Published in:

01-07-2007 | Original Article

Neridronate inhibits angiogenesis in vitro and in vivo

Authors: D. Ribatti, B. Nico, D. Mangieri, N. Maruotti, V. Longo, A. Vacca, F. P. Cantatore

Published in: Clinical Rheumatology | Issue 7/2007

Abstract

The effects of the amino-bisphosphonate neridronate on endothelial cell functions involved in angiogenesis, namely, proliferation and morphogenesis on Matrigel were tested in vitro, whereas its effects on angiogenesis were studied in vivo, by using the chick embryo chorioallantoic membrane (CAM) assay. In vitro, neridronate inhibited endothelial cell proliferation in a dose-dependent fashion, peaking at 30 μM. At the same concentration, neridronate inhibited fibroblast growth factor-2 (FGF-2)-induced capillary-like tube formation in the morphogenesis assay on Matrigel. In vivo, when tested in the CAM assay, neridronate again displayed the capability to inhibit FGF-2-induced angiogenesis. Overall, these results suggest that anti-angiogenesis by neridronate could be used to treat a wide spectrum of angiogenesis-dependent diseases, including certain chronic inflammatory diseases and cancer.

Bukowski JF, Dascher CC, Das H (2005) Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 328:746–750PubMedCrossRef

Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061PubMedCrossRef

Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482–492PubMedCrossRef

Hamma-Kourbali Y, Di Benedetto M, Ledoux D, Oudar O, Leurox Y, Lecouvey M, Kraemer M (2003) A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun 310:816–823PubMedCrossRef

Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H, Imaizumi T (2004) Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 165:1865–1874PubMed

Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Aliminti A, Di Cocco B, D’Agosto G, Bordignon V, Trento E, Cognetti F (2005) Zolendronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69:35–43PubMedCrossRef

Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L, Tonini G (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151PubMedCrossRef

Ribatti D, Nico B, Vacca A, Roncali L, Burri PH, Djonov V (2001) Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat Rec 264:317–324PubMedCrossRef

Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143–4155PubMed

10.

Kueng K, Silfer E, Eppenberger V (1989) Quantitation of cells cultured on 96-well plates. Anal Biochem 182:16–19PubMedCrossRef

11.

Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M (1997) New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 34:455–463PubMedCrossRef

12.

Folkman J (1971) Tumor angiogenesis: therapeutic implications. New Engl J Med 285:1182–1186PubMedCrossRef

13.

Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31PubMedCrossRef

14.

Brown DL, Robbins R (1999) Developments in the therapeutic applications of bisphosphonates. J Clin Pharmacol 39:651–660PubMedCrossRef

15.

Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97(3 Suppl):840–847PubMedCrossRef

16.

Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T, Lahteenmaki T, Ylitalo P, Porsti I (1998) Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 83:125–131PubMed

17.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostrate in castrated rats. Cancer Res 62:6538–6544PubMed

18.

Sebbah-Louriki M, Colombo BM, el Manouni D, Martin A, Salzmann JL, Leroux Y, Perret GY, Crepin M (2002) A new phenylacetate-bisphoshonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res 22:3925–3931PubMed

19.

Giraudo E, Inoue M, Hanahan D (2004) An amino-biphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623–633PubMedCrossRef

Title: Neridronate inhibits angiogenesis in vitro and in vivo
Authors: D. Ribatti
B. Nico
D. Mangieri
N. Maruotti
V. Longo
A. Vacca
F. P. Cantatore
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 7/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-006-0455-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Neridronate inhibits angiogenesis in vitro and in vivo

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2007

Improving management of musculoskeletal disorders in primary care: the Joint Adventures Program

Tacrolimus as a reinforcement therapy for a patient with MPO-ANCA-associated diffuse alveolar hemorrhage

Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis

Vasculitis in siblings with familial Mediterranean fever: a report of three cases and review of the literature

CPPD complicating other forms of inflammatory arthritis

The effect of infliximab on chemokines in patients with rheumatoid arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page